Introducing 1,3-beta-d-glucan for screening and diagnosis of invasive fungal diseases in Australian high-risk haematology patients: is there a clinical benefit?
Saved in:
| Title: | Introducing 1,3-beta-d-glucan for screening and diagnosis of invasive fungal diseases in Australian high-risk haematology patients: is there a clinical benefit? |
|---|---|
| Authors: | Garnham K; Centre for Infectious Diseases and Microbiology Laboratory Services, New South Wales Health Pathology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Sydney, New South Wales, Australia.; Marie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, Sydney, New South Wales, Australia., Halliday CL; Centre for Infectious Diseases and Microbiology Laboratory Services, New South Wales Health Pathology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Sydney, New South Wales, Australia.; Marie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, Sydney, New South Wales, Australia., Rai NJ; Clinical Trials Unit, Centre for Infectious Diseases and Microbiology, Westmead Hospital, Sydney, New South Wales, Australia., Jayawardena M; Centre for Infectious Diseases and Microbiology Laboratory Services, New South Wales Health Pathology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Sydney, New South Wales, Australia., Hasan T; Clinical Trials Unit, Centre for Infectious Diseases and Microbiology, Westmead Hospital, Sydney, New South Wales, Australia.; Department of Infectious Diseases, Westmead Hospital, Sydney, New South Wales, Australia., Kok J; Centre for Infectious Diseases and Microbiology Laboratory Services, New South Wales Health Pathology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Sydney, New South Wales, Australia.; Marie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, Sydney, New South Wales, Australia.; Clinical Trials Unit, Centre for Infectious Diseases and Microbiology, Westmead Hospital, Sydney, New South Wales, Australia.; Department of Infectious Diseases, Westmead Hospital, Sydney, New South Wales, Australia., Nayyar V; Department of Intensive Care Medicine, Westmead Hospital, Sydney, New South Wales, Australia., Gottlieb DJ; Department of Haematology Medicine, Westmead Hospital, Sydney, New South Wales, Australia., Gilroy NM; Marie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, Sydney, New South Wales, Australia.; Clinical Trials Unit, Centre for Infectious Diseases and Microbiology, Westmead Hospital, Sydney, New South Wales, Australia.; Department of Infectious Diseases, Westmead Hospital, Sydney, New South Wales, Australia., Chen SC; Centre for Infectious Diseases and Microbiology Laboratory Services, New South Wales Health Pathology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Sydney, New South Wales, Australia.; Marie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, Sydney, New South Wales, Australia.; Clinical Trials Unit, Centre for Infectious Diseases and Microbiology, Westmead Hospital, Sydney, New South Wales, Australia.; Department of Infectious Diseases, Westmead Hospital, Sydney, New South Wales, Australia. |
| Source: | Internal medicine journal [Intern Med J] 2022 Mar; Vol. 52 (3), pp. 426-435. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Blackwell Science Asia Country of Publication: Australia NLM ID: 101092952 Publication Model: Print Cited Medium: Internet ISSN: 1445-5994 (Electronic) Linking ISSN: 14440903 NLM ISO Abbreviation: Intern Med J Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
